Corona Remedies Ltd

Corona Remedies Ltd has demonstrated a significant shift in technical momentum, moving from a mildly bullish stance to a more confident bullish trend. This change is underpinned by positive signals from key technical indicators including MACD, Bollinger Bands, and Dow Theory, suggesting a strengthening price momentum that investors should closely monitor.

Surging to an all-time high of Rs 2261.4 on 4 Aug 2026, Corona Remedies Ltd has demonstrated remarkable price momentum, supported by a confluence of bullish technical indicators and sustained gains over recent sessions.

Corona Remedies Ltd, a prominent player in the Pharmaceuticals & Biotechnology sector, achieved a significant milestone on 4 August 2026 as its stock price reached an all-time high, closing at Rs 2,225. This marks a notable moment in the company’s market journey, reflecting strong performance and sustained investor confidence.

Corona Remedies Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a subtle shift in its technical momentum, moving from a bullish to a mildly bullish stance. This change is underscored by a combination of technical indicators including MACD, RSI, and moving averages, signalling a cautiously optimistic outlook for investors as the stock edges closer to its 52-week high.

Surging to a fresh 52-week and all-time high of Rs 2208.05 on 3 Aug 2026, Corona Remedies Ltd demonstrated robust price momentum despite a modest underperformance relative to its sector. This milestone caps a year-long journey from a 52-week low of Rs 1336.95, underscoring the stock’s technical resilience amid a mixed market backdrop.

Corona Remedies Ltd, a prominent player in the Pharmaceuticals & Biotechnology sector, reached a significant milestone on 3 August 2026 as its stock price touched an all-time high of Rs. 2,208.05. This achievement reflects the company’s robust financial performance and sustained growth trajectory over recent quarters.

Corona Remedies Ltd., a small-cap pharmaceutical company with a market capitalisation of ₹12,951 crores, delivered an impressive first quarter performance for FY2027, with consolidated net profit surging 30.11% year-on-year to ₹60.11 crores. The strong results, announced recently, propelled the stock to ₹2,097.60 as of July 31, 2026, marking a gain of 0.38% on the day and continuing its remarkable year-to-date rally of 51.36%.

Corona Remedies Ltd has seen its investment rating upgraded from Hold to Buy, driven primarily by a marked improvement in technical indicators alongside sustained fundamental strength. The upgrade reflects a comprehensive reassessment across quality, valuation, financial trends, and technical parameters, signalling renewed investor confidence in this small-cap pharmaceutical player.

Corona Remedies Ltd has witnessed a notable shift in its technical momentum, upgrading from a mildly bullish to a bullish trend, supported by key indicators such as MACD, RSI, and moving averages. This transition, coupled with strong relative returns against the Sensex, positions the small-cap pharmaceutical company favourably in the current market environment.

Corona Remedies Ltd has reached a significant milestone by touching a new 52-week high of Rs.2147.6 on 30 July 2026, marking a notable moment in the stock’s recent performance and reflecting sustained momentum in the Pharmaceuticals & Biotechnology sector.

Extending its recent rally, Corona Remedies Ltd touched a fresh all-time high of Rs 2,147.60 on 30 Jul 2026, outperforming the Sensex and its sector consistently across multiple timeframes.

Corona Remedies Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a subtle shift in its technical momentum, moving from a bullish to a mildly bullish stance. Despite a slight dip in its share price, the stock continues to outperform the broader market, supported by a complex interplay of technical indicators that suggest cautious optimism among investors.

Surging to a new all-time high of Rs 2,139.55 on 27 Jul 2026, Corona Remedies Ltd has demonstrated remarkable price momentum, supported by a confluence of bullish technical indicators across multiple timeframes. This milestone caps a period of sustained gains, with the stock outperforming its sector despite a modest underperformance on the day.

Corona Remedies Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 20 July 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 26 July 2026, providing investors with the latest insights into the company’s performance and outlook.

Corona Remedies Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a mildly bullish to a bullish trend. Despite a modest day decline of 2.23%, the stock’s technical indicators suggest strengthening momentum, offering investors a nuanced perspective amid broader market fluctuations.

Surging to an all-time high of Rs 2128.45 on 21 Jul 2026, Corona Remedies Ltd has demonstrated remarkable price momentum, outpacing its sector and marking a significant milestone in its trading history.